Incannex Healthcare Limited (IXHL) Joel Latham, CEO

Incannex is a clinical stage pharmaceutical development company that is

developing unique medicinal cannabinoid pharmaceutical products and psychedelic

medicine therapies for the treatment of anxiety disorders, obstructive sleep

apnoea (OSA), traumatic brain injury (TBI)/concussion, lung inflammation (ARDS,

COPD, asthma, bronchitis), rheumatoid arthritis and inflammatory bowel disease.

U.S. FDA approval and registration, subject to ongoing clinical success, is

being pursued for each drug and therapy under development. Each indication

represents major global markets and currently have no, or limited, existing

registered pharmacotherapy (drug) treatments available to the public.